Literature DB >> 31189541

Derivation and Validation of a Novel Risk Score to Predict Overcorrection of Severe Hyponatremia: The Severe Hyponatremia Overcorrection Risk (SHOR) Score.

Jason D Woodfine1,2, Manish M Sood1,2,3,4, Thomas E MacMillan5,6, Rodrigo B Cavalcanti5,6, Carl van Walraven7,2,3,4.   

Abstract

BACKGROUND AND OBJECTIVES: Osmotic demyelination syndrome is the most concerning complication of severe hyponatremia, occurring with an overly rapid rate of serum sodium correction. There are limited clinical tools to aid in identifying individuals at high risk of overcorrection with severe hyponatremia. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We identified all patients who presented to a tertiary-care hospital emergency department in Ottawa, Canada (catchment area 1.2 million) between January 1, 2003 and December 31, 2015, with serum sodium (corrected for glucose levels) <116 mmol/L. Overcorrection was determined using 14 published criteria. Latent class analysis measured the independent association of baseline factors with a consensus overcorrection status on the basis of the 14 criteria, and was summarized as a risk score, which was validated in two cohorts.
RESULTS: A total of 623 patients presented with severe hyponatremia (mean initial value 112 mmol/L; SD 3.2). The prevalence of no, unlikely, possible, and definite overcorrection was 72%, 4%, 10%, and 14%, respectively. Overcorrection was independently associated with decreased level of consciousness (2 points), vomiting (2 points), severe hypokalemia (1 point), hypotonic urine (4 points), volume overload (-5 points), chest tumor (-5 points), patient age (-1 point per decade, over 50 years), and initial sodium level (<110 mmol/L: 4 points; 110-111 mmol/L: 2 points; 112-113 mmol/L: 1 point). These points were summed to create the Severe Hyponatremic Overcorrection Risk (SHOR) score, which was significantly associated with overcorrection status (Spearman correlation 0.45; 95% confidence interval, 0.36 to 0.49) and was discriminating (average dichotomized c-statistic 0.77; 95% confidence interval, 0.73 to 0.81). The internal (n=119) and external (n=95) validation cohorts had significantly greater use of desmopressin, which was significantly associated with the SHOR score. The SHOR score was significantly associated with overcorrection status in the internal (P<0.001) but not external (P=0.39) validation cohort.
CONCLUSIONS: In patients presenting with severe hyponatremia, overcorrection was common and predictable using baseline information. Further external validation of the SHOR is required before generalized use.
Copyright © 2019 by the American Society of Nephrology.

Entities:  

Keywords:  Acid-Base Imbalance; Cohort Studies; Consciousness; Consensus; Deamino Arginine Vasopressin; Demyelinating Diseases; Emergency Service, Hospital; Glucose; Neoplasms; Prevalence; Sodium; Tertiary Care Centers; Vomiting; Water-Electrolyte Imbalance; hypokalemia; hyponatremia; latent class analysis; osmotic demyelination syndrome; prediction

Mesh:

Substances:

Year:  2019        PMID: 31189541      PMCID: PMC6625619          DOI: 10.2215/CJN.12251018

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  24 in total

Review 1.  Presentation of multivariate data for clinical use: The Framingham Study risk score functions.

Authors:  Lisa M Sullivan; Joseph M Massaro; Ralph B D'Agostino
Journal:  Stat Med       Date:  2004-05-30       Impact factor: 2.373

2.  Clinical practice guideline on diagnosis and treatment of hyponatraemia.

Authors:  Goce Spasovski; Raymond Vanholder; Bruno Allolio; Djillali Annane; Steve Ball; Daniel Bichet; Guy Decaux; Wiebke Fenske; Ewout J Hoorn; Carole Ichai; Michael Joannidis; Alain Soupart; Robert Zietse; Maria Haller; Sabine van der Veer; Wim Van Biesen; Evi Nagler
Journal:  Eur J Endocrinol       Date:  2014-02-25       Impact factor: 6.664

3.  Diagnosis, evaluation, and treatment of hyponatremia: expert panel recommendations.

Authors:  Joseph G Verbalis; Steven R Goldsmith; Arthur Greenberg; Cynthia Korzelius; Robert W Schrier; Richard H Sterns; Christopher J Thompson
Journal:  Am J Med       Date:  2013-10       Impact factor: 4.965

4.  Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia.

Authors:  Robert W Schrier; Peter Gross; Mihai Gheorghiade; Tomas Berl; Joseph G Verbalis; Frank S Czerwiec; Cesare Orlandi
Journal:  N Engl J Med       Date:  2006-11-14       Impact factor: 91.245

Review 5.  Incidence and prevalence of hyponatremia.

Authors:  Ashish Upadhyay; Bertrand L Jaber; Nicolaos E Madias
Journal:  Am J Med       Date:  2006-07       Impact factor: 4.965

Review 6.  Age-associated abnormalities of water homeostasis.

Authors:  Laura E Cowen; Steven P Hodak; Joseph G Verbalis
Journal:  Endocrinol Metab Clin North Am       Date:  2013-04-17       Impact factor: 4.741

7.  Hypertonic saline for hyponatremia: risk of inadvertent overcorrection.

Authors:  Hashim K Mohmand; Dany Issa; Zubair Ahmad; Joseph D Cappuccio; Ruth W Kouides; Richard H Sterns
Journal:  Clin J Am Soc Nephrol       Date:  2007-10-03       Impact factor: 8.237

8.  Intravenous conivaptan for the treatment of hyponatraemia caused by the syndrome of inappropriate secretion of antidiuretic hormone in hospitalized patients: a single-centre experience.

Authors:  Juan Carlos Q Velez; Shirley J Dopson; Donna S Sanders; Tracie A Delay; John M Arthur
Journal:  Nephrol Dial Transplant       Date:  2010-01-11       Impact factor: 5.992

9.  Hypertonic saline and desmopressin: a simple strategy for safe correction of severe hyponatremia.

Authors:  Lonika Sood; Richard H Sterns; John K Hix; Stephen M Silver; Linlin Chen
Journal:  Am J Kidney Dis       Date:  2012-12-23       Impact factor: 8.860

10.  Successful long-term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with satavaptan (SR121463B), an orally active nonpeptide vasopressin V2-receptor antagonist.

Authors:  Alain Soupart; Peter Gross; Jean-Jacques Legros; Sándor Alföldi; Djillali Annane; Hassan M Heshmati; Guy Decaux
Journal:  Clin J Am Soc Nephrol       Date:  2006-10-11       Impact factor: 8.237

View more
  5 in total

1.  Overcorrection versus osmotic demyelination syndrome: what should we watch out for during management of symptomatic chronic hyponatremia?

Authors:  Hyun Lee Ko; Sung Woo Lee
Journal:  Kidney Res Clin Pract       Date:  2022-05-09

2.  Risk factors for overcorrection of severe hyponatremia: a post hoc analysis of the SALSA trial.

Authors:  Huijin Yang; Songuk Yoon; Eun Jung Kim; Jang Won Seo; Ja-Ryong Koo; Yun Kyu Oh; You Hwan Jo; Sejoong Kim; Seon Ha Baek
Journal:  Kidney Res Clin Pract       Date:  2022-02-22

3.  Etiology Analysis and Diagnosis and Treatment Strategy of Traumatic Brain Injury Complicated With Hyponatremia.

Authors:  Jianhua Zhang; Wensheng Dong; Xianghong Dou; Jinjin Wang; Peng Yin; Hui Shi
Journal:  Front Surg       Date:  2022-02-21

4.  A Survey of Hospital Pharmacy Guidelines for the Administration of 3% Sodium Chloride in Children.

Authors:  Siddharth A Shah; Juan C Ayus; Michael L Moritz
Journal:  Children (Basel)       Date:  2022-01-03

5.  Risk of Overcorrection in Rapid Intermittent Bolus vs Slow Continuous Infusion Therapies of Hypertonic Saline for Patients With Symptomatic Hyponatremia: The SALSA Randomized Clinical Trial.

Authors:  Seon Ha Baek; You Hwan Jo; Soyeon Ahn; Kristianne Medina-Liabres; Yun Kyu Oh; Jung Bok Lee; Sejoong Kim
Journal:  JAMA Intern Med       Date:  2021-01-01       Impact factor: 21.873

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.